Keenova Therapeutics Plc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Keenova Therapeutics Plc (MNK) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Keenova Therapeutics Plc vs Its Competitors
- TTM: Trailing 12-month revenue of 1,413M vs 250,573M combined for tracked competitors (0.6% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+32.4% annualized vs trailing 12 months), vs decelerating (-6.5%) for its tracked peer group.
- Growth: Keenova Therapeutics Plc generated 11.4% revenue growth year over year in Q1 2026, vs 8.7% for its tracked competitors combined.
- Profitability: Its -24.3% net margin compares with 9.5% for the peer group.
- Peer revenue share: Keenova Therapeutics Plc accounted for 0.8% of combined revenue among its tracked peer group, up from 0.8% a year earlier.
- Peer differentiation: Revenue per employee of $0.88M compares with $0.97M for the peer group (0.9x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
MNK Sales vs. its Competitors, Q1 2026
Keenova Therapeutics Plc reported revenue growth of 11.36 % year on year in Q1 2026, above its competitors' combined revenue growth of 8.69 %.
With a net margin of -24.27 %, Keenova Therapeutics Plc reported lower profitability than its competitors (9.51 %).
Keenova Therapeutics Plc generated 0.79 % of the combined sales of its peer group, up from 0.77 % a year earlier.
Keenova Therapeutics Plc vs. its Competitors, Q1 2026
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Keenova Therapeutics Plc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Keenova Therapeutics Plc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (1) | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (5) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Keenova Therapeutics Plc's competitor groups requires a Commercial License.
For context: the Major Pharmaceutical Preparations industry grew revenue 7.2% year over year, combined, vs 11.4% for Keenova Therapeutics Plc. Keenova Therapeutics Plc's share of combined industry revenue moved from 0.06% to 0.06%, a gain of 0.00 percentage points.
Keenova Therapeutics Plc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Keenova Therapeutics Plc | No | No | No | No |
| Competitors combined (50) | ||||
| High-Confidence Competitors (1) | ||||
| Similar Growth & Profitability (8) | 0.00 % (0 of 8) | 0.00 % (0 of 8) | 0.00 % (0 of 8) | 62.50 % (5 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
MNK Stock Performance relative to its Competitors
MNK Stock Performance relative to High-Confidence Competitors
MNK Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Spruce Biosciences Inc | 282.9% | Outperformed |
| 2 | Ironwood Pharmaceuticals inc | 282.9% | Outperformed |
| 3 | Eton Pharmaceuticals Inc | 282.9% | Outperformed |
| 4 | Avadel Pharmaceuticals Plc | 282.9% | Outperformed |
| 5 | Evoke Pharma Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Keenova Therapeutics Plc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Keenova Therapeutics Plc's Comment on Competition and Industry Peers
Publicly Traded Peers of Keenova Therapeutics Plc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Keenova Therapeutics Plc | 13.47 | 1,413.00 |
| Abbvie Inc | 471,581.88 | 64,386.00 |
| Amgen Inc | 227,462.72 | 38,095.00 |
| Pfizer Inc | 163,675.28 | 63,696.00 |
| Vertex Pharmaceuticals Inc | 134,661.38 | 12,587.20 |
| Regeneron Pharmaceuticals Inc | 79,738.50 | 15,534.70 |
| SUBTOTAL | 1,209,487.08 | 270,356.97 |
Sign in to see all competitors of Keenova Therapeutics Plc.
Sources: Keenova Therapeutics Plc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Keenova Therapeutics Plc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Keenova Therapeutics Plc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| ANI Pharmaceuticals Inc. | Named by the company | 85% |
| Teva Pharmaceutical Industries Limited | Named by the company | 85% |
| Ovid Therapeutics Inc | Named by the company | 85% |
| Lannett Company Inc | Named by the company | 85% |
| Beyond Air Inc | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Keenova Therapeutics Plc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Keenova Therapeutics Plc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Amgen Inc | Reportable 100.00 % |
| Pfizer Inc | U.S. Commercial Division 52.92 % |
| Vertex Pharmaceuticals Inc | Pharmaceuticals 100.00 % |
| Teva Pharmaceutical Industries Limited | United States Segment 41.09 % |
| Viatris Inc | Developed Markets 57.61 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Keenova Therapeutics Plc.
Keenova Therapeutics Plc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Keenova Therapeutics Plc | 13 | 883,125 | -358,188 |
| Abbvie Inc | 471,582 | 1,129,579 | 110,807 |
| Amgen Inc | 227,463 | 2,930,385 | 672,538 |
| Pfizer Inc | 163,675 | 849,280 | 58,267 |
| Vertex Pharmaceuticals Inc | 134,661 | 31,079,506 | 10,877,037 |
| Regeneron Pharmaceuticals Inc | 79,739 | 1,008,092 | 280,902 |
| PEERS TOTAL | 1,209,474 | 973,327 | 77,734 |
Sign in to see all peers for Keenova Therapeutics Plc.
Keenova Therapeutics Plc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Pfizer Inc | United States 58.91 % |
| Vertex Pharmaceuticals Inc | United States 61.68 % |
| Teva Pharmaceutical Industries Limited | Europe 30.49 % |
| Perrigo Company Plc | United States 57.24 % |
| Amphastar Pharmaceuticals Inc | US 92.91 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Keenova Therapeutics Plc.
Keenova Therapeutics Plc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Major Pharmaceutical Preparations industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (341 companies).| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 42.29 % | 64.89 % (avg) | -22.6 pp |
| Operating Margin | -35.61 % | industry median | +1.8 pp |
| EBITDA Margin | -24.81 % | -7.21 % (avg) | -17.6 pp |
| Capital Intensity (Capex / Revenue) | - | 4.92 % (avg) | - |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Keenova Therapeutics Plc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | -4.71 % | -0.19 % | -1.65 % | -30.01 % | -0.21 % | - | 0.00 % | -36.69 % |
| Operating Margin | 13.04 % | -115.71 % | -57.62 % | -29.44 % | -9.19 % | -9.19 % | -9.19 % | -27.56 % |
| Return on Invested Capital | 2.22 % | -20.07 % | -15.99 % | -9.94 % | -2.63 % | -2.79 % | -4.04 % | -5.35 % |
| P/E | 1.0x | - | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Keenova Therapeutics Plc's Strategic Group Map
Every company in Keenova Therapeutics Plc's industry and named-competitor list, plotted by trailing 12-month revenue growth and operating margin. Keenova Therapeutics Plc is shown in red; its closest peers by combined growth, margin and ROIC (the Similar Growth & Profitability group above) are labeled.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Keenova Therapeutics Plc's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Keenova Therapeutics Plc falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Keenova Therapeutics Plc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Latest-quarter revenue run-rate is accelerating (+32.4% annualized vs trailing 12 months).
Weaknesses
- Return on equity 42.9 points below the industry aggregate.
- Underperforming the U.S.A. 500 over the trailing 12 months.
Opportunities
No rule matched.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-6.5% annualized).
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Keenova Therapeutics Plc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Keenova Therapeutics Plc | 1.07 | 3.15 | 1.11 |
| Abbvie Inc | 0.16 | 0.75 | - |
| Amgen Inc | 0.46 | 1.26 | 5.86 |
| Pfizer Inc | 0.04 | 1.24 | 0.71 |
| Vertex Pharmaceuticals Inc | 1.34 | 2.85 | - |
| Regeneron Pharmaceuticals Inc | 0.57 | 3.74 | 0.06 |
Sign in to see all peers for Keenova Therapeutics Plc.
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Keenova Therapeutics Plc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Keenova Therapeutics Plc | Q1 2026 | -7.4 % | - |
| Abbvie Inc | Q2 2026 | +10.2 % | +284.3 % |
| Amgen Inc | Q2 2026 | +9.5 % | +65.9 % |
| Pfizer Inc | Q2 2026 | +2.6 % | - |
| Vertex Pharmaceuticals Inc | Q2 2026 | +12.5 % | +6.5 % |
| Regeneron Pharmaceuticals Inc | Q2 2026 | +16.7 % | -6.8 % |
| PEERS TOTAL | -0.4 % | - |
Sign in to see all peers for Keenova Therapeutics Plc.
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Keenova Therapeutics Plc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Keenova Therapeutics Plc | Q1 2026 | -1.1 % | -49.5 % |
| Abbvie Inc | Q2 2026 | -1.3 % | +19.7 % |
| Amgen Inc | Q2 2026 | -6.6 % | +39.0 % |
| Pfizer Inc | Q2 2026 | +8.3 % | -13.8 % |
| Vertex Pharmaceuticals Inc | Q2 2026 | +20.0 % | -23.0 % |
| Regeneron Pharmaceuticals Inc | Q2 2026 | +109.2 % | +9.7 % |
Sign in to see all peers for Keenova Therapeutics Plc.
Keenova Therapeutics Plc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Keenova Therapeutics Plc | - | - | - |
| Abbvie Inc | 4.68% | 9.11% | - |
| Amgen Inc | 9.48% | 13.08% | 89.32% |
| Pfizer Inc | 2.12% | 2.53% | 4.91% |
| Vertex Pharmaceuticals Inc | 16.88% | 19.97% | 23.31% |
| Regeneron Pharmaceuticals Inc | 10.60% | 11.83% | 13.81% |
Sign in to see all peers for Keenova Therapeutics Plc.
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Keenova Therapeutics Plc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Keenova Therapeutics Plc | - | 0.01 |
| Abbvie Inc | 75.22 | 7.32 |
| Amgen Inc | 25.97 | 5.97 |
| Pfizer Inc | 37.66 | 2.57 |
| Vertex Pharmaceuticals Inc | 30.77 | 10.70 |
| Regeneron Pharmaceuticals Inc | 18.63 | 5.13 |
| PEERS AVERAGE | 57.85 | 4.47 |
Sign in to see all peers for Keenova Therapeutics Plc.
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.